Tropical Diseases Travel Medicine and Vaccines, published by SPRINGERNATURE, stands at the forefront of research in the fields of infectious diseases and public health, with an impressive impact factor that signifies its relevance and influence. Since its inception in 2015, this peer-reviewed journal has maintained an open access policy, ensuring that cutting-edge research on tropical diseases and travel medicine is readily available to researchers, professionals, and students worldwide. The journal currently ranks in the Q2 Quartile for both Infectious Diseases and Public Health, Environmental and Occupational Health, reflecting its substantial contribution to these critical areas of study. With a strong Scopus rank of #176 in Public Health and #138 in Infectious Diseases, it serves as a vital platform for innovative studies that advance understanding and response strategies related to tropical diseases. For its vast audience, Tropical Diseases Travel Medicine and Vaccines not only acts as a bridge connecting researchers with practical applications but also nurtures academic discourse essential for future advancements in global health.

The JOURNAL OF INFECTIOUS DISEASES, published by OXFORD UNIV PRESS INC, is a leading peer-reviewed journal dedicated to advancing the understanding of infectious diseases through high-quality research. With an impressive impact factor reflecting its prominence in the field—ranking in the Q1 category for both Immunology and Allergy and Infectious Diseases—this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike. Its extensive history, spanning over a century since its inception in 1904, highlights its established authority and commitment to the field. Based in the United Kingdom, the journal covers essential topics from clinical management to epidemiological trends, providing vital insights that inform practice and policy. Although the journal is not open access, it remains accessible to a wide audience, ensuring that critical research continues to drive innovation and best practices in infectious disease management.

The Japanese Journal of Infectious Diseases, published by the National Institute of Infectious Diseases in Japan, serves as a vital platform for researchers, clinicians, and public health professionals committed to advancing the field of infectious disease science. With an ISSN of 1344-6304 and an E-ISSN of 1884-2836, this journal has maintained its academic rigor since its inception in 1961 and continues to contribute significantly to the global understanding of infectious diseases. The journal holds a Q3 ranking in the categories of Infectious Diseases, Miscellaneous Medicine, and Medical Microbiology as of 2023, reflecting its important role in disseminating impactful research. With many articles available through Open Access, it ensures wide accessibility to the latest discoveries and insights. Researchers can expect to find high-quality studies that address critical challenges in the control and prevention of infectious diseases, making this journal an essential resource for anyone engaging in this critical field.

Expert Review of Vaccines, published by Taylor & Francis Ltd, is a pivotal open access journal that has established itself as a leading source of peer-reviewed articles focusing on vaccine research, development, and policy. With an impressive categorization in the top quartile (Q1) across various domains including Drug Discovery, Immunology, Molecular Medicine, and Pharmacology for 2023, this journal plays a crucial role in disseminating high-quality scientific findings that drive advances in the field. Located in the United Kingdom, it serves a global audience of researchers, healthcare professionals, and students seeking to stay abreast of cutting-edge developments in vaccination strategies and technologies. The journal’s Scopus ranks further attest to its excellence, boasting remarkable placements in Pharmacology and Drug Discovery, reflecting its impact and reach. Since transitioning to an open access format in 2023, the journal has enhanced accessibility to vital research, empowering a broader audience to contribute to and engage with the discourse surrounding vaccines. As the field of immunization continues to evolve, Expert Review of Vaccines remains a cornerstone for those committed to advancing knowledge and practice in this essential area of health science.

Infektsiya i Immunitet, published by the esteemed SANKT-PETERSBURG-NIIEM IMENI PASTERA, is a prominent open access journal that has been disseminating vital research findings since 2011. Focusing on the fields of immunology and infectious diseases, this journal serves as a critical platform for scholars, professionals, and students in the Russian Federation and beyond. With an ISSN of 2220-7619 and an E-ISSN of 2313-7398, it currently holds a Q4 ranking in 2023 for both Immunology and Infectious Diseases, along with notable quartile standings in related fields. Despite its emerging status, Infektsiya i Immunitet provides valuable insights and contributes to the growing discourse on immunity and infection prevention strategies, making it an essential resource for those invested in advancing knowledge and enhancing public health outcomes. Researchers can conveniently access its wealth of articles and studies that bridge theoretical understanding and practical implications in their respective domains.

Eurosurveillance is a prestigious journal dedicated to the field of epidemiology, public health, and infectious diseases, published by the European Centre for Disease Prevention and Control since 1996. With an impressive Q1 ranking across various categories, including Epidemiology and Public Health, it consistently stands at the forefront of research dissemination, making it an invaluable resource for researchers, professionals, and students alike. The journal boasts an outstanding reputation, as evidenced by its Scopus rankings, where it ranks in the top 1% to 3% in multiple relevant categories. As an Open Access publication, Eurosurveillance ensures that vital findings are freely accessible to a global audience, fostering collaboration and innovation in the fight against infectious diseases. With a dedicated reach from 2001 to 2024, the journal addresses contemporary challenges in public health and virology, reinforcing its significance in shaping policies and research initiatives across the world.

Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.

Future Science OA is an esteemed open-access journal published by FUTURE SCI LTD, dedicated to advancing knowledge in the fields of biotechnology and medicine. Established in 2015, this journal has rapidly gained recognition within the scientific community, evidenced by its impressive ranking in both General Medicine (Rank #100/636, 84th percentile) and Biotechnology (Rank #145/311, 53rd percentile) as per Scopus metrics. With a Q2 category quartile in both fields as of 2023, Future Science OA provides a vital platform for researchers, professionals, and students to share groundbreaking research and innovative ideas. Notably, being an open-access journal allows for a wider dissemination of knowledge, ensuring equal access to high-quality research for practitioners and scholars alike. Based in the United Kingdom, Future Science OA is committed to fostering collaboration and dialogue within the scientific community, making it a cornerstone resource for advancing the future of the life sciences.